While direct oral anticoagulants (DOACs) hold some advantages over vitamin K antagonists, DOAC adverse effects, including bleeding, present a clinical challenge in frail older patients.
Article InformationCorresponding Author: Anne-Laure Sennesael, MSc, Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Av E Mounier, 72 B1.72.02, 1200 Brussels, Belgium (email@example.com).
Published Online: August 3, 2015. doi:10.1001/jamainternmed.2015.3589.
Conflict of Interest Disclosures: None reported.
Additional Contributions: Anne-Sophie Larock, MSc, Department of Pharmacy, CHU Dinant Godinne UcL Namur, Yvoir, Belgium, contributed to the medication history and collection of data; François Mullier, PhD, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), CHU Dinant Godinne UcL Namur, Yvoir, Belgium, and Jonathan Douxfils, MPharm, Department of Pharmacy, NTHC, Namur Research Institute for Life Sciences, University of Namur, Belgium, performed drug monitoring and interpretation of the data. All 3 persons provided a critical review of the manuscript and were not compensated for their contributions.